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ABSTRACT

Comparison of Testosterone Replacement Therapy
Medications for Treatment of Hypogonadism

Testosterone replacement therapy (TRT) is one treatment option for men with hypogonadism.
When TRT is prescribed, effectiveness, patient compliance, cost, and potential side effects
should be considered and utilized to develop an individualized treatment plan. Depo-testosterone
is the most cost-efficient TRT option and is only administered every 2 weeks which may
improve patient compliance, although the dose interval can be adjusted to once per week.
Androderm is the most efficacious TRT medication, with up to 92% of patients reaching normal
testosterone levels. Testim and Vogelxo have the fewest reported side effects. We recommend
depo-testosterone as a first line treatment option.

Comparison of Testosterone Replacement Therapy
Medications in the Treatment of Hypogonadism
Testosterone replacement therapy (TRT) is one possible treatment option for men with
hypogonadism and may be beneficial for older men in whom testosterone levels are suboptimal.1
TRT has been shown to produce a significant improvement in quality of life2 and may help
support cardiovascular health.3 In addition, when hypogonadal men are treated with TRT,
obesity, type 2 diabetes mellitus, and exercise capacity may improve.3
When TRT is a viable treatment option, routes of administration, effectiveness, cost, and
potential side effects should be considered. In US pharmacies, TRT is available via
intramuscular, nasal, buccal, and topical routes. The purpose of this article is to review TRT
medications the patient can self-administer and then compare their effectiveness, likelihood of
promoting patient compliance, monthly cost (before insurance), and potential side effects.
Methods
Six electronic databases were searched to identify studies and literature reviews relating
to TRT efficacy, side effects, and cost. Databases included CINAHL, MEDLINE, Pubmed,
Cochrane Library, Health Source: Nursing/Academic Edition, and Web of Science. UpToDate
and Epocrates were also reviewed.
Research published from 2011-2016 in English was included initially, but yielded few
published studies. While the majority of data were published from 2000-2011, one sentinel study
was published in 1997. Therefore, inclusion criteria were expanded to include published articles
from 1997-2016.
Research focused on US TRT prescription medications the patient could self-administer.
Efficacy and side effects were unavailable for some medications in the literature, necessitating

inclusion of data from the package inserts as published either on the Food and Drug
Administration (FDA) website or the manufacturer website. To differentiate independently
funded studies from manufacturer data, the terms “independently evaluate” and “independent”
are utilized. Search terms included: hypogonadism, testosterone, testosterone replacement
therapy, efficacy, cost, price, and low testosterone.
Results
Ten studies met inclusion criteria: five studies independently evaluated the efficacy and
side effects of a single TRT medication4-8 and five studies compared the efficacy and side effects
of two or more TRT medications.9-13 The product monograph was evaluated for all 13
prescription medications for all delivery routes and strengths.
Testosterone Replacement Therapy Precautions
TRT may not be appropriate for some patients, namely those with breast or prostate
cancer, a prostate nodule or induration, or a prostate specific antigen (PSA) above 4 ng/ml or
above 3 ng/ml in male patients at high risk for prostate cancer. TRT is contraindicated in men
who have a hematocrit higher than 50%, severe obstructive and untreated sleep apnea, severe
urinary tract symptoms, or heart failure.14
Adverse effects occur with any TRT medication and include: 1) erythrocytosis; 2) urinary
retention; 3) acne; 4) reduced sperm production/infertility; and 5) testicular atrophy/failure,
although most of these adverse effects are dose dependent.15-16 Any male patient wanting more
children should be carefully informed of the risks with TRT medication and infertility and
testicular atrophy/failure. Less common side effects include: 1) gynecomastia; 2) adrenergic
alopecia; 3) worsening benign prostatic hyperplasia; 4) obstructive sleep apnea (OSA) or
worsening of already existing OSA; 5) fluid retention; 6) growth of an already existing prostate

cancer; and 7) breast cancer.15-16 Practice guidelines for monitoring patients after initiation of
TRT are available through the Endocrine Society at https://www.endocrine.org/education-andpractice-management/clinical-practice-guidelines
Injectable Testosterone
Depo-testosterone (testosterone cypionate). Depo-testosterone is the most popularly
prescribed TRT medication in the US17 and is a long-acting testosterone commonly prescribed
once every 2-weeks. The most common dose is 200 milligrams (mg) in 1 milliliter (ml)18
although it is available in two doses: 100 mg/ml and 200 mg/ml. The 100 mg/ml is available in a
10 ml vial, while the 200 mg/ml is available in 10 ml vial or 1 ml vial. When calculated from the
most commonly prescribed dose, the average cost per month is $22.70 for the 100 mg/ml (10 ml
vial) and $18.45 for the 200 mg/ml (10 ml vial).19 The 200 mg/ml in the 1 ml vial is considerably
more expensive at $98.07/month (See Table 1).19
Depo-testosterone is commonly prescribed in the US and has been used safely since
receiving FDA approval in 1979, however the literature is scarce regarding its effectiveness and
side effects. The benefit of depo-testosterone is the twice monthly dosing, however, the
disadvantage of intramuscular administration may negatively affect patient compliance.18 When
administered, testosterone levels quickly increase and then gradually decrease until the next
injection. Thus, there may be fluctuations in testosterone levels. This variability can be
minimized by shortening the amount of time between injections (i.e. 100 mg/week rather than
200 mg/every other week).18
Delatestryl (testosterone enanthate). Delatestryl is a long-lasting testosterone injection
that only needs to be administered approximately every 2-weeks. Delatestryl has been used for
TRT for decades and is available at 200 mg/ml in a 5 ml vial. The most commonly prescribed

dose is 1 ml every 2-weeks. Deletestryl is available as a generic and costs, on average,
$23.46/month (See Table 1).19
Generally, Delatestryl is well tolerated by patients. Adverse reactions are rarely reported
but include the potential for anaphylaxis. Thus, patients should be observed immediately
following the injection for any signs of anaphylaxis. Benefits of Delatestryl for TRT include
twice/month dosing although the need for regular injections may affect patient compliance.20
Since 2014, Deletestryl has been in short supply and may be difficult to obtain.21
Nasal Testosterone
Natesto, a testosterone-based nasal gel, is self-administered three times per day.
Approximately 40 minutes after administration, testosterone levels return to normal, although
Natesto’s half-life is widely variable, between 10 and 100 minutes.5 Each bottle of Natesto
delivers approximately 60 actuations but, when taken as commonly prescribed, 180 actuations
constitute a 1-month supply, therefore, three bottles are needed each month. Natesto is not
available in generic form and costs $233.07 per bottle or $699.21 per month (See Table 1).17
According to a study funded by the manufacturer, side effects occurred in <9% of
patients during the 180-day clinical trial and most commonly included nasopharyngitis,
rhinorrhea, parosmia, headache and nasal discomfort and scabbing (See Table 2).20 Benefits of
Natesto include a less invasive delivery method and less risk of inadvertently transferring the gel
to a partner or child.18 One notable disadvantage of Natesto is the three times per day dosing,
which may be inconvenient for some patients.18
Buccal Testosterone
Striant, the only available buccal form of testosterone, is available in a 30 mg tablet and
commonly prescribed twice per day.19 Manufacturer data from one 12-week clinical study

showed Striant provided steady testosterone levels for 86.6% of subjects.20 The most common
side effect in long-term extension trials was gingivitis (32.6%). Other side effects occurred in
<10% of subjects but included gum irritation/pain/edema, bitter taste, and headache (See Table
2). 20 With no generic substitute, the average cost for a 1-month supply of Striant is $724.77 (See
Table 1).19 Advantages to buccal testosterone include quick delivery of medication using a less
invasive method.
Two head-to-head comparison studies measuring serum total testosterone levels have
been published on Striant9,11 one of which compared Striant to the Androderm patch11 and the
second of which compared Striant to Androgel 1% packets.9 The mean total testosterone level
was similar between Striant and Androgel.9 However, Korbonits et al.11 concluded that Striant
was superior to the Androderm patch because Striant testosterone levels were always within
normal limits whereas Androderm testosterone levels fell below normal within the first 2 hours
of placing the patch (See Table 2).
Two additional independent studies have been conducted with Striant.6,8 In both studies,
Striant was found to effectively elevate serum testosterone levels within 24 hours of initiating
treatment.6,8 No side effects were reported in one study;6 however, 16.3% of subjects in the
Wang, Swerdloff, et al. study reported gum-related irritation.8
Transdermal Testosterone
Androderm patch. The Androderm patch is available in two different strengths: 2 mg
and 4 mg.22 The patch should be applied to non-scrotal skin and then replaced every 24 hours,
rotating sites with each application. The per month cost of Androderm is $195.03 for 30 patches
(See Table 1).19

Manufacturer data show Androderm produces normal testosterone levels in 92% of
patients.20 When compared to Deletestryl (testosterone enanthate) in a 6-month trial, Androderm
normalized testosterone in 82% of subjects while Deletestryl normalized testosterone for 72% of
subjects.20 However, 37% of patients using Androderm had pruritis at the application site and
12% had a burn-like blister that formed under the patch (See Table 2).20
One independent study found Androderm to normalize testosterone levels in subjects, as
well as mimic the natural circadian pattern of testosterone during a day.4 However, Androderm
also caused skin irritation in 56% of subjects and burn-like blisters at the application site in 18%
of subjects.4
Korbonits et al.12 found that although Striant and Androderm both returned testosterone
levels to normal; however, over a 24 hour treatment period subjects receiving Striant maintained
normal testosterone levels whereas subjects receiving Androderm had lower than normal
testosterone levels within the first 2 hours of applying the patch. For this reason, and because
there were few side effects in either group, Korbonits et al. concluded that Striant was superior to
Androderm (See Table 2).11
In two additional independent studies, Androderm was compared to Testim13 and
Androgel.12 Steidle et al.13 concluded that treatment with two Testim 1% gel tubes per day (100
mg total) was superior to Androderm in normalizing testosterone levels and had fewer dermalrelated side effects, such as erythema, rash, pruritis, and irritation. Mazer et al.12 reported similar
efficacy and localized skin-related side effects between Androderm and Androgel (See Table 2).
Gel pumps/packets/tubes. When transdermal testosterone gel is prescribed as a pump,
the most common dosing schedule is 2-4 pumps each day. Packets and tubes are both designed
for single use, meaning a 1-month supply would take 30 packets or 30 tubes.

Androgel is available in a pump and packet form at 1% or 1.62% doses. Similarly,
Fortesta 2% and Axiron 2% are available as a pump. Vogelxo 1% is available as a pump, a
packet, and a tube. Testim 1% is only available in tubes. All transdermal gel formulations carry
the risk of unintentionally transferring medication to a partner or children (See Table 2).
Average cost for a 1-month supply of testosterone gel pumps/packets/tubes varies. The
most expensive testosterone gel is Axiron 2% pump at $630.78.19 The next most expensive
testosterone gel is Androgel costing $516.41 for the 1.62% packets and $510.77 for the 1.62%
pump.17 All remaining formulas are similar in price for a 1-month supply (See Table 1).17
Four independent studies compared the efficacy and side effects of testosterone gel in
packets and tubes to other testosterone medications.9,10,12,13 Androgel was found to have similar
efficacy and occurrence of side effects when compared to Striant and Androderm.9,12 When
comparing Testim to Androderm, Testim was superior at achieving normal testosterone levels
and had a lower incidence of side effects.13 In a crossover study comparing Androgel and
Testim, researchers concluded that Testim was more efficacious than Androgel although
Androgel had fewer side effects (See Table 2).10
Wang, Cunningham, et al.7 compared the efficacy of Androgel 1% packets in varying
doses (ie 1 or 2 packets daily) by examining mean serum and free testosterone levels. When
titrated, Androgel 1% packets resulted in patient outcomes similar to injectable testosterone or
other transdermal formulas.7 Additionally, Androgel 1% gel packets did not cause skin irritation
and were found to be safe and effective, even in long-term treatment.7
Manufacturer data regarding efficacy were also reviewed. Axiron was the most effective
gel resulting in normal testosterone levels in 89% of subjects. Effectiveness of Androgel 1% and
1.62% was reported as 87% and 81.6% after titration, respectively. Fortesta was efficacious in

77.5% of subjects and Testim and Volgelxo resulted in normal testosterone levels in 74% of
subjects after titration.20
Package insert information regarding side effects of Testim, Vogelxo, Axiron, Fortesta,
and Androgel 1% and 1.62% were reviewed. Testim and Vogelxo had the least occurrence of
side effects (<5%) the most common of which was skin irritation. With Axiron and Androgel 1%
and 1.62% side effects were found in less than 10% of subjects. The most common side effect of
Axiron was skin irritation while acne was the most common side effect of Androgel 1% and
1.62%. Finally, Fortesta had the highest occurrence of side effects at 17%, the most common of
which was skin irritation (See Table 2).20
Discussion
TRT medications administered every day most consistently maintain testosterone levels
within a normal range. Since all transdermal TRT medications are prescribed on a once per day
dosing schedule, it would appear that transdermal TRT preparations, in general, are more
efficacious than TRT medications with more frequent or less frequent dosing schedules.
Compliance is another consideration when prescribing TRT for patients since the number
of medication doses each day can have a significant effect on patient compliance. Indeed, there is
an inverse relationship between the number of medication doses and patient compliance: the
higher the number of medication doses in a day, the lower the patient compliance.23 Some
testosterone medications, such as Natesto and Striant, are prescribed three times per day or two
times per day, respectively, and may negatively affect patient compliance. Using this same logic,
it would seem that depo-testosterone and Delatestryl would be associated with greater patient
compliance because these two injected testosterone medications only need to be administered
every 2-weeks.

A review of all testosterone medications revealed that the most cost-efficient TRT
medications were injectable formulations, namely depo-testosterone and Delatestryl. Depotestosterone is commonly prescribed at 200mg/ml every 2-weeks and is available for dispense in
a 10ml vial for $92.2919, although there is variation among some prescribers regarding the dose
interval. For example, some providers opt to prescribe 100mg every week to avert the medication
trough that can occur with every other week dosing. The 10ml vial of depo-testosterone,
however, would have enough medication for 5-months, for an average monthly cost of $18.45. In
comparison, Delatestryl is commonly prescribed at 200mg/ml every 2-weeks and can be
dispensed in a 5ml vial for $23.46.17 The 5ml vial of Delatestryl would contain enough doses for
2.5-months for an average monthly cost of $23.46. When compared to the cost of transdermal
patches at $195.03 per month or the cost of nasal gel at $699.21 per month, the cost difference is
notable (See Table 1).
Finally, side effects of each TRT medication should be carefully evaluated. The
injectable testosterone depo-testosterone is not well studied, even though it has been available
the longest and is the most frequently prescribed of all types of TRT medications with seemingly
few side effects. Less than 9% of Natesto users experience side effects which are usually
associated with the nasopharynx, such as nasopharyngitis. Over 32% of patients taking Striant
report gingivitis as a side effect (See Table 2).20
There are also side effects with transdermal testosterone medications. Androderm has the
highest occurrence of side effects with up to 56% of patients reporting skin irritation4 (See Table
2), and 12-18% reporting a burn-like blister at the application site.20 The greatest concern
regarding the testosterone transdermal gel is unintentional transdermal transfer to children or
women.20 Androgel 1.62% manufacturer data show that average testosterone levels in female

partners increased by 280% after contact with the application site. However, when the
application site was covered by a shirt, average testosterone levels in female partners increased
by only 6-13%. Testim is the only transdermal testosterone that showed no change in female
partner testosterone levels after covering the application site with a shirt.20
Implications for Nurse Practitioners
The Endocrine Society4 recommends healthcare providers select a TRT with
consideration of which medication effectively stabilizes testosterone levels, aligns with patient
preference (increasing compliance), is affordable, and causes the fewest side effects. Depotestosterone is the most affordable TRT medication and has the highest compliance, assuming
the patient can tolerate injections. Therefore, depo-testosterone may be a good first line therapy
option. Depo-testosterone may not control testosterone levels as tightly as the transdermal
testosterone that is administered every day because it is only injected once every 2-weeks. For
patients who are sensitive to the testosterone peaks and troughs of depo-testosterone, we
recommend altering the administration schedule to a half dose every week rather than a full dose
every 2-weeks.
Androderm patches have the highest efficacy (up to 92%)20 and are a good second line
therapy option for patients who cannot tolerate injections. Androderm patches are the next most
affordable TRT option and offer consistent dosing without the peaks and troughs of injected
testosterone. However, the patient should be warned about the risk of side effects, namely skin
irritation.4
For patients who cannot tolerate depo-testosterone injections or the Androderm patch, we
recommend Testim gel as a third line option. Testim is the next most affordable TRT option, has
an efficacy of 74%20, and is associated with fewer side effects than Androderm.4,20 All TRT gel

medications carry the risk for unintentional transfer to a partner or to children, although
according to research Testim has the lowest risk of unintentional transfer as long as the
application site is covered with a shirt.20
Limitations/Further Research
Few independent research studies have been published in the last 5 years. Additionally,
medication costs may vary between states and pharmacies and can be affected by insurance
coverage. All patients taking TRT medications need labs, which would necessitate further cost.
Furthermore, injected TRT medications may warrant a clinic visit to administer the medication,
unless the patient and/or family can administer injections. Finally, patients receiving injected
TRT may need an altered dosing schedule such as a half dose every week rather than a full dose
every other week.
Conclusion
There are different TRT treatment options that should be selected with careful
consideration of efficacy, compliance, cost, and side effects. All methods of testosterone delivery
improve patient testosterone levels. In consideration of TRT medication efficacy, patient
compliance, medication cost, and common medication side effects, we recommend depotestosterone, Androderm, and Testim as the first, second, and third line treatment option.
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Table 1
Types of Testosterone Medications
Trade Name

Generic

Route

Available Dosing

depotestosterone

testosterone
cypionate

IM

100 mg/ml
200 mg/ml

Delatestryl

testosterone
enanthate

IM

200 mg/ml

Natesto

N/A

Nasal gel

5.5 mg each actuation

Striant

N/A

Buccal

30 mg

Androderm

N/A

Patch

2 mg
4 mg

AndroGel
1% or

testosterone 1%

Gel pump

1.62%

testosterone
1.62%
N/A
testosterone 2%
testosterone 1%

Gel pump
Gel pump
Gel pump

AndroGel
1% or

testosterone 1%

Gel packet

1.62%

testosterone
1.62%
testosterone 1%

Axiron 2%
Fortesta 2%
Vogelxo 1%

Vogelxo 1%

1%-12.5mg/1.25g

Common Dose

Average Cost/Month
(calculated from common dose)

Q 2 weeks

100mg/ml (10ml vial) = $22.7019
200mg/ml (10ml vial) = $18.4519
200mg/ml (1ml vial) = $98.0719

200 mg/ml17

Q 2 weeks

200mg/ml (5ml vial) = $23.4617

Nasal
11 mg (1 actuation per nostril) 17

TID

3 bottles (30 days) = $699.2117

BID

60 tablets = $724.7719

QD

30 patches = $195.0319

Injectable
200 mg/ml19

Buccal
30 mg19
Transdermal Patch
4 mg22
Transdermal Gel Pump
50mg (4 pumps)19

1.62%-20.25mg/1.25g

Gel packet

Common
Frequency

40.5mg (2 pumps)19

30mg /1.5ml
10mg/0.5g
12.5 mg/1.25g

60 mg (2 pumps) 19
40mg (4 pumps) 2
50mg (4 pumps)17
Transdermal Gel Packets
1%-25mg/2.5g
50mg (1 packet)19
1%-50mg/5g
1.62%-20.25mg/1.25g
1.62%-40.5mg/2.5g
1%-25mg/2.5g
1%-50mg/5g

QD

1 bottle 1.62% (30 days) $510.7717
QD
QD
QD

1 bottle (30 days) $630.78 19
1 bottle (30 days) = $281.8017
2 bottles (30 days) = $283.6917

QD

30 packets 1% = $309.2517

40.5mg (1 packet)19
50mg (1 packet) 19

2 bottles 1% (30 days) $309.2417

30 packets 1.62% = $516.4117
QD

30 packets 1% = $270.3017

Testim 1%

testosterone 1%

Gel tube

50mg/5g

Vogelxo 1%

testosterone 1%

Gel tube

50mg/5g

Transdermal Gel Tubes
50mg17
50mg19

QD

30 tubes = $268.2517

QD

30 tubes = $268.2517

Table 2
Testosterone Medication Comparison
Trade Name

Advantages

depotestosterone

Q 2 weeks; three-fold increase
in testosterone within 2 days;
most affordable19
>72% effective20; affordable17

Delatestryl
Natesto

Levels normalize in 40
minutes5; less invasive

Striant

>86.6% effective20; levels
normalize in 24 hours6,8; less
invasive

Androderm

>92% effective20; two doses
for titration22; mimics natural
circadian pattern of
testosterone4; more affordable
than all medications except IM
testosterone19

AndroGel

>87% effective; two doses for
titration; less skin irritation
compared to some IM and
transdermal formulas7

Disadvantages
Injectable
IM20; levels gradually decrease
until next injection
IM20; in short supply21

Nasal
Upper respiratory side effects in
<9% of patients20; TID dosing18;
cost17
Buccal
Gingivitis in >32.6% of patients20;
BID dosing19; most expensive19

Efficacy in
Comparison Studies
Equal to AndroGel7
Equal to AndroGel7

Superior to Androderm11
Equal to AndroGel9

Transdermal Patch
Skin irritation in >56% of
Superior to Deletestryl20
patients4; lower than normal
Equal to Androgel12
testosterone within first 2 hours of
application11
Transdermal Gel
Risk for unintentional transfer20;
side effects in <10% of patients
(acne most common)20; restrictions
on bathing/swimming20

Side Effects in
Comparison Studies

Equal to Androderm12
Equal to depo-testosterone7
Equal to Deletestryl7
Equal to Striant9

Equal to AndroGel9

Equal to Androgel12

Equal to Androderm12
Equal to Striant9
Fewer side effects than Testim10

Axiron

>89% effective20

Fortesta

>77.5% effective20

Vogelxo

>74% effective20

Testim

>74% effective20

Risk for unintentional transfer20;
most expensive transdermal gel19;
side effects in <10% of patients20;
restrictions on bathing/swimming20
Risk for unintentional transfer20;
side effects in >17% of patients20;
restrictions on bathing/swimming20
Risk for unintentional transfer20;
side effects in <5% of patients20;
restrictions on bathing/swimming20
Risk for unintentional transfer20;
side effects in <5% of patients20;
restrictions on bathing/swimming20

Superior to Androderm13
Superior to AndroGel10

Fewer side effects than
Androderm13

